Clinical Cancer Research AACR Conference on Cancer Prevention Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kantarjian, H. M.
Right arrow Articles by Cortes, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kantarjian, H. M.
Right arrow Articles by Cortes, J. E.
Clinical Cancer Research Vol. 8, 2177-2187, July 2002
© 2002 American Association for Cancer Research

Clinical Trials

Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-{alpha}

Follow-Up Results1

Hagop M. Kantarjian2, Moshe Talpaz, Susan O’Brien, Terry L. Smith, Francis J. Giles, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia-Manero, Jean-Pierre J. Issa, Michael Andreeff, Steven M. Kornblau, Charles Koller, Milosav Beran, Michael Keating, Mary Beth Rios, Jenny Shan, Debra Resta, Renaud Capdeville, Kimberly Hayes, Maher Albitar, Emil J. Freireich and Jorge E. Cortes3

Departments of Leukemia [H. M. K., S. O., F. J. G., S. F., D. A. T., G. G-M., J-P. J. I., M. A., S. M. K., C. K., M. B., M. K., M. B. R., J. S., M. A., E. J. F., J. E. C.], Biostatistics [T. L. S.], Bioimmunotherapy [M. T.], and Hematopathology [K. H.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Novartis, 4002 Basel, Switzerland [D. R., R. C.]

We treated 261 patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) in chronic phase after failure of IFN-{alpha} with the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate (400 mg/day given p.o.) and analyzed hematological and cytogenetic responses, long-term prognosis, factors associated with achievement of major cytogenetic response and survival, and comparative survival in similar patients treated with other regimens. Median patient age was 55 years; 34% were 60 years or older, and median chronic-phase duration was 33 months. Overall, 94% achieved a complete hematological response, and 71% had a cytogenetic response [major (Ph+ cells <35%) in 62% and complete in 45%]. At a median follow-up of 17 months, 241 patients (92%) were still taking imatinib mesylate; estimated 18-month freedom from progression and survival rates were 93 and 96%. Multivariate analysis of factors associated with major cytogenetic response identified long chronic phase, marrow basophilia, high percentage of Ph+ cells before therapy, and prior hematological resistance to IFN-{alpha} as being adverse factors. This model was used to generate good-, intermediate- and poor-risk subgroups who had estimated major cytogenetic response rates of 93, 53, and 34%, respectively. Univariate analysis in terms of survival identified leukocytosis, high percentages of peripheral and marrow blasts, marrow basophilia, and the presence of cytogenetic clonal evolution as being adverse factors. Achieving a cytogenetic response at 3 or 6 months of therapy was associated with prolonged survival. In a subset analysis, survival rates among 161 patients with Ph-positive CML after hematological or cytogenetic failure after IFN-{alpha} who had been treated with imatinib mesylate were better than those for similar patients treated previously with other regimens. In summary, imatinib mesylate is highly effective in chronic-phase CML after IFN-{alpha} failure. We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival.




This article has been cited by other articles:


Home page
 The OncologistHome page
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist, April 1, 2008; 13(4): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. G. Oehler, T. Gooley, D. S. Snyder, L. Johnston, A. Lin, C. C. Cummings, S. Chu, R. Bhatia, S. J. Forman, R. S. Negrin, et al.
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
Blood, February 15, 2007; 109(4): 1782 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood, September 15, 2006; 108(6): 1809 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Ault, H. Kantarjian, S. O'Brien, S. Faderl, M. Beran, M. B. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, et al.
Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib
J. Clin. Oncol., March 1, 2006; 24(7): 1204 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Martinelli, I. Iacobucci, G. Rosti, F. Pane, M. Amabile, F. Castagnetti, D. Cilloni, S. Soverini, N. Testoni, G. Specchia, et al.
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
Ann. Onc., March 1, 2006; 17(3): 495 - 502.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 971 - 979.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Cortes, M. Talpaz, S. O'Brien, D. Jones, R. Luthra, J. Shan, F. Giles, S. Faderl, S. Verstovsek, G. Garcia-Manero, et al.
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Clin. Cancer Res., May 1, 2005; 11(9): 3425 - 3432.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al.
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
Blood, March 15, 2005; 105(6): 2281 - 2286.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J. F. Seymour, S. Durrant, P. Browett, A. P. Schwarer, C. Arthur, et al.
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Blood, November 1, 2004; 104(9): 2926 - 2932.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. M. Kantarjian, J. E. Cortes, S. O'Brien, R. Luthra, F. Giles, S. Verstovsek, S. Faderl, D. Thomas, G. Garcia-Manero, M. B. Rios, et al.
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}
Blood, October 1, 2004; 104(7): 1979 - 1988.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Blood, June 15, 2004; 103(12): 4396 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak, D. Thomas, et al.
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
Blood, April 15, 2004; 103(8): 2873 - 2878.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kantarjian, S. O'Brien, J. Cortes, F. Giles, J. Shan, M. B. Rios, S. Faderl, S. Verstovsek, G. Garcia-Manero, W. Wierda, et al.
Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-{alpha} Failure and in Late CML-CP, Comparison with Historical Controls
Clin. Cancer Res., January 1, 2004; 10(1): 68 - 75.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Cortes, F. Giles, S. O'Brien, D. Thomas, G. Garcia-Manero, M. B. Rios, S. Faderl, S. Verstovsek, A. Ferrajoli, E. J. Freireich, et al.
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome--positive chronic myeloid leukemia after failure of interferon-{alpha}
Blood, July 1, 2003; 102(1): 83 - 86.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Branford, Z. Rudzki, S. Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J. F. Seymour, C. Arthur, et al.
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Blood, July 1, 2003; 102(1): 276 - 283.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Cortes, M. Talpaz, F. Giles, S. O'Brien, M. B. Rios, J. Shan, G. Garcia-Manero, S. Faderl, D. A. Thomas, W. Wierda, et al.
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
Blood, May 15, 2003; 101(10): 3794 - 3800.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
A. Hole and D. Blake
A review of imatinib mesilate in the treatment of patients with gastrointestinal stromal tumours and chronic myeloid leukaemia
Journal of Oncology Pharmacy Practice, March 1, 2003; 9(1): 1 - 14.
[Abstract] [PDF]

Home page
 BloodHome page
H. M. Kantarjian, M. Talpaz, S. O'Brien, F. Giles, G. Garcia-Manero, S. Faderl, D. Thomas, J. Shan, M. B. Rios, and J. Cortes
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
Blood, January 15, 2003; 101(2): 473 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Kantarjian, M. Talpaz, J. Cortes, S. O'Brien, S. Faderl, D. Thomas, F. Giles, M. B. Rios, J. Shan, and R. Arlinghaus
Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia
Clin. Cancer Res., January 1, 2003; 9(1): 160 - 166.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. M. Kantarjian, J. E. Cortes, S. O'Brien, F. Giles, G. Garcia-Manero, S. Faderl, D. Thomas, S. Jeha, M. B. Rios, L. Letvak, et al.
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
Blood, January 1, 2003; 101(1): 97 - 100.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.